Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics Inc (CGTX) is a clinical-stage biopharmaceutical company pioneering treatments for neurodegenerative disorders through its sigma-2 receptor modulator platform. This page serves as the definitive source for verified news and official announcements related to CGTX's research, clinical trials, and corporate developments.
Investors and industry observers will find timely updates on clinical progress for lead candidate CT1812, financial disclosures, and strategic collaborations with research institutions. The curated content includes press releases on trial milestones, peer-reviewed study publications, and regulatory filings, providing essential insights for informed decision-making.
All materials are organized to help users efficiently track developments in Alzheimer's disease, dementia with Lewy bodies, and retinal disorder research. Bookmark this page to maintain current awareness of CGTX's scientific advancements and corporate initiatives within the competitive neurodegenerative therapeutics landscape.
Cognition Therapeutics (NASDAQ: CGTX) reported positive results from its Phase 2 SHINE trial for CT1812, an oral treatment for mild-to-moderate Alzheimer's disease. The study showed:consistent cognitive improvement compared to placebo across all measures, with a ~40% mean improvement in cognitive outcomes. CT1812 demonstrated a favorable safety profile with mostly mild or moderate adverse events. Significant changes were observed in neurofilament light chain, a marker of neurodegeneration. The 100mg dose showed particularly promising results, informing future dose selection. These findings suggest that CT1812's amyloid oligomer antagonism mechanism may have potential as a monotherapy or in combination with approved drugs for Alzheimer's and related dementias.
Cognition Therapeutics (NASDAQ: CGTX) will host an investor webcast on July 29, 2024, to discuss results from the Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer's disease. The study enrolled 153 adults, randomized to receive 100mg or 300mg of CT1812 or placebo daily for six months. Clinical findings, safety, cognitive and functional endpoints will be presented at the Alzheimer's Association's International Conference in Philadelphia. Additional presentations will cover biomarker and proteomic analyses from CSF samples, and results of a meta-analysis from the SPARC study and SHINE-A participants. The webcast will feature company management, study investigator Dr. Everard Vijverberg, and Alzheimer's expert Dr. Martin J. Sadowski.
Cognition Therapeutics (NASDAQ: CGTX) announced that their Phase 2 SHINE study results for CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, will be presented at the Alzheimer’s Association's International Conference (AAIC) in Philadelphia from July 28 to August 1, 2024.
The study's abstracts cover clinical efficacy, safety, and biomarker findings. Key abstracts include:
- Clinical efficacy results from the Phase 2 SHINE study (Abstract #89115).
- CSF phosphoproteomics biomarker analysis (Abstract #95147).
- Topline CSF biomarker outcomes (Abstract #95767).
- Exploratory CSF proteomics biomarker outcomes (Abstract #95770).
Cognition will also provide additional information about their Alzheimer’s disease program and CT1812 at booth #731 in the Exhibit Hall.
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent research showing Aβ oligomers binding to synapses in Alzheimer's patients and how CT1812 can reverse this binding and reduce toxicity. Highlights include the use of quantitative EEG as a biomarker in the Phase 2 ‘SEQUEL’ study, which showed improvements in synaptic function and brain connectivity after four weeks of CT1812 treatment. Dr. Hamby presented proteomic analysis results demonstrating CT1812's positive effects on proteins and pathways linked to Alzheimer's. The discussion was moderated by Dr. Anthony Caggiano, featuring Dr. Mary Hamby, Dr. Everard Vijverberg, and Dr. Tara Spires-Jones.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) reported financial results for Q1 2024 and provided business updates. They completed enrollment of 130 participants in the SHIMMER study for Alzheimer's and DLB, with topline results expected mid-2024. The company also raised $11.9 million in a public offering and presented research findings at conferences.
Financially, the company has $34.7 million in cash and $62.3 million in grant funds. Research and development expenses increased to $10.6 million, leading to a net loss of $9.2 million for the quarter.
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024. The study aims to develop a disease-modifying therapy for DLB by targeting Aβ and α-synuclein oligomers.
FAQ
What is the current stock price of COGNITION THERAPEUTICS (CGTX)?
What is the market cap of COGNITION THERAPEUTICS (CGTX)?
